• Home
  • ABOUT US
  • Human Cardiomyocytes

History Introducing NEXEL’s History

2026’s

  • Sep
    "AI-Integrated hiPSC-CM Functional Cardiotoxicity Screening Platform” FDA iSTand LOI ACCEPTANCE
    Jul
    Cardiosight®-S approved for FDA iSTand LOI as a NAMs DDT for cardiac safety assessment
    May
    Signed global distribution and strategic partnership MOU with ChemPartner (China)
    Apr
    Published paper on precision cardiotoxicity evaluation combining cardiomyocytes and AI prediction (Archives of Toxicology, IF: 10.9)
    Mar
    Registered US patent for cardiac safety evaluation using cardiomyocytes
    Mar
    Filed Korean patent for impedance-based precision cardiac safety testing method using cardiomyocytes
    Mar
    Filed Korean patent for impedance-based precision hepatotoxicity testing method using hepatocytes
    Mar
    Commenced mass production of heart organoids
    Mar
    Signed JV establishment contract among NEXEL, CMIC, and DNP for marketing & business of iPSC-based products
    Jan
    Signed Master Services Agreement (MSA) with Celltrion for drug evaluation utilizing hiPSC models

2025’s

  • Oct
    Hosted 1st NEXEL Innovation Talk – New ERA of Organoid (1st NEXEL Academic Event)
    Aug
    Filed Korean patent for micropattern development to improve cardiomyocyte maturation
    Aug
    Filed Korean patent for assessing drug effects on cardiomyocyte sodium ion channels
    Jul
    Signed MOU with Korea Brain Research Institute (KBRI) for brain organoid research and commercial technology development
    Jul
    Commenced mass production of cardiac organoids
    Mar
    Registered Korean patent for cardiac organoid drug evaluation method
    Jan
    Converted U.S. subsidiary Celogics into a 100% wholly-owned subsidiary

2024’s

  • Dec
    Cardiosight®-S listed in "Comprehensive Cardiac Arrhythmia Evaluation Guidelines" published by MFDS
    Dec
    Registered Japanese patent for cardiac/cardiomyocyte organoid differentiation induction methods
    Jun
    Registered Korean patent for cardiac/cardiomyocyte organoid differentiation induction methods
    May
    Signed non-exclusive agency contract with Scientist.com (USA) for NEXEL product sales
    Apr
    Awarded Best Poster Award at 2024 Korean Organoid Society
    Apr
    Signed tech transfer and business alliance agreement with DNP (Japan) (JPY 250M)
    Apr
    Signed non-exclusive agency contract with PELO Biotech (Germany) for NEXEL product sales (hiPSC-derived products)
    Jan
    Registered Korean patent for cardiac safety evaluation using cardiomyocytes

2023’s

  • Nov
    Filed Korean patent for heart disease modeling using cardiac organoids
    Nov
    Awarded KEIT President Award for Outstanding R&D Company in Bio-Health at 2023 Bio Industry Day (MOTIE)
    Sep
    Secured JPY 100M strategic investment and signed business cooperation agreement with CMIC (Japan's largest CRO)
    Aug
    Awarded Best Poster Award at 2023 Korean Society for Stem Cell Research
    Jun
    Filed Chinese patent for cardiac safety evaluation using cardiomyocytes
    Jan
    Filed US, European, Japanese, and Chinese patents for myocardial organoids and a method for inducing differentiation into cardiac organoids
    Jan
    Filed US, European, and Japanese patents for cardiac organoid drug evaluation method

2022’s

  • Dec
    Registered patent for vascular dementia treatment technology using neurons
    Dec
    Signed technology transfer agreement with KIT for hiPSC-derived liver organoid manufacturing technology
    Dec
    Filed Korean patent for cardiac organoid drug evaluation method
    Apr
    Obtained ISO 17025 certification and KOLAS accreditation for drug evaluation assay using hiPSC-CMs

2021’s

  • Dec
    Participated in ICH Guideline Revision / HESI research; NEXEL Cardiosight®-S cardiomyocytes selected and supplied as standard cells
    Oct
    Established joint venture Celogics in Seattle, USA, with Curi Bio
    Oct
    Awarded Best Poster Award at 2021 Korean Organoid Society
    Jul
    Awarded Best Poster Award at 2021 Korean Society for Stem Cell Research
    Apr
    Participated in publishing "Guide to Cardiovascular Safety Pharmacology Assessment" hosted by MFDS

2020’s

  • Jan
    Officially launched hiPSC model-based drug evaluation service (NeXST)

2019’s

  • Jun
    Registered patent for mass production differentiation of cardiomyocytes

2018’s

  • Jun
    Obtained INNOBIZ Certification
    May
    Acquired commercial license utilizing human induced pluripotent stem cells from iPS Academia Japan (Kyoto University)
    Mar
    Launched hiPSC-derived cardiomyocytes (Cardiosight®-S) and neurons (Neurosight®-S)
    Mar
    Obtained ISO 9001 certification for hiPSC-derived functional cell product manufacturing

2017’s

  • Nov
    Launched hiPSC-derived hepatocyte product (Hepatosight®-S)

2016’s

  • Dec
    Acquired patent technology transfer from Korea University Research & Business Foundation (6 patents)
    Nov
    Acquired technology transfer from KIT for stem cell-derived cardiomyocyte differentiation induction methods
    Mar
    Certified as an Affiliated Research Institute
    Feb
    Certified as a Venture Business

2015’s

  • May
    Renamed to NEXEL Co., Ltd.

2013’s

  • Mar
    Signed research cooperation MOU with Korea University Anam Hospital

2012’s

  • Sep
    Established NEXEL Bio
Beyond conventional boundaries,
we deliver a bold new paradigm.

  • iPSC technologyCONTACT

    Contact Information

    • Address: 8F, 55 Magokdong-ro, Gangseo-gu, Seoul, Republic of Korea(07802)

    • Business Registration No.: 109-86-37282
    • CEO: Choongseong Han

    • Tel : +82-2-2088-8886
    • Fax: +82-2-2088-8884
    • E-mail : support@nexel.co.kr